Cipla Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0b7w2b3nwv5404srpfssog0v.pdf

Key Takeaways


One India: A Weak Quarter, A Confident Outlook

Umang Vohra: "I think the way you make portfolio choices here will be -- will perhaps be the most important."

North America: Pipeline vs. Revlimid Phasing

Umang Vohra: "Actually, it's a little indeterminate. And it depends on when Revlimid -- the impact of Revlimid and how it comes off. If we could see a larger impact of Revlimid in quarter 3, we could see it in quarter 4 or in quarter 2, right? So we don't know that, and it's very difficult to give a guidance range."

Biosimilars: Building a Third Engine

Umang Vohra: "in some way, a biosimilar engine for a company like us will begin to mimic an investment return ratio a little bit more than a complex generics product, but not too far from it."

Margins & Cost Structure


Regulatory & Facility Updates


International Markets (Ex-U.S.)


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin23.5% to 24.5% rangeFull year FY26
U.S. revenue aspirationCloser to $1 billionFY27
First U.S. biosimilar launchFilgrastim (supportive care oncology)Q2 FY26
Generic Advair U.S. launchLikely H2 launchFY26
Peptide launches in U.S.2 to 3 assetsFY26
Generic Symbicort launchKey respiratory launchLater in FY26
Own biosimilar assetsVia JV investment'29-'30 time period
India business growthGrow in line with industryNext 3 quarters
Indore facility reinspectionExpected any timeNow to February

Key Metrics

MetricQ1 FY26
Revenue₹6,957 cr, +4% YoY
One India revenue₹3,000+ cr (breached threshold for first time in an opening quarter), +6% YoY; 44% of global revenue
North America revenue$226 million
One Africa revenue growth+11% YoY in USD terms
South Africa revenue growth+6% YoY in ZAR terms
EMEU revenue growth+8% YoY in USD terms
EBITDA margin25.6%, broadly flat YoY
Gross margin68.8%, +156 bps YoY
R&D spend₹432 cr, 6.2% of revenue
Profit after tax₹1,298 cr, 18.7% of sales, +10.2% YoY
Effective tax rate27%, flat YoY
Net cash balance₹10,379 cr as of June 30; total debt ₹459 cr
Full-year EBITDA margin guidance23.5% to 24.5%
Chronic segment share of branded Rx sales61.5% as per IQVIA MAT June '25
Brands in ₹100 cr+ club29, 5 added this quarter
Albuterol U.S. market share19.5%, ranked #1 in Albuterol MDI market
One Africa private market secondary growth5.6%, vs market growth of 3.8%